Application no. and date | 17709189.9 (espacenet) (Federated) (European Patent Register), 20170220 | Patent/reg. no. and date | DK/EP 3419625, 20210407 | Publication date | 20190102 | Priority no. and date | US 201662298121 P, 20160222, US 201662420661 P, 20161212 | EP pub. no. and date |
EP 3419625 20190102 | Effective date | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | Applicant ref. no. | BT/GP/164841 | Inventor | LAFFITTE, Bryan, c/o Novartis Institute for Functional Genomics Inc. dba The Genomics Institute of the Novartis Research Foundation (GNF) 10675 John Jay Hopkins Drive
San Diego, California 92121, US, BADMAN, Michael, c/o Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US, LINDGREN, Sam, c/o Novartis Pharma AG Postfach
4002 Basel, CH, CHEN, Jin, c/o Novartis Pharmaceuticals Corporation One Health Plaza
East Hanover, New Jersey 07936-1080, US | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | Opponent | | IPC Class | A61K 31/46 (2006.01) , A61K 31/4748 (2006.01) , A61K 31/497 (2006.01) , A61K 31/506 (2006.01) , A61P 1/00 (2006.01) , A61P 1/16 (2006.01) | Title | FREMGANGSMÅDER TIL ANVENDELSE AF FXR-AGONISTER | Int. application no. | IB2017050963 | Int. publication no. | WO2017145041 | Related patent (certificate) | | Status | Bortfaldet | Pædiatrisk forlængelse | - | Udløbsdato for pædiatrisk forlængelse | - |
|